Full-Time

Staff Engineer

Embedded Services Scrum Master

Updated on 7/21/2026

Stryker

Stryker

10,001+ employees

Manufactures orthopedic and surgical medical devices

Compensation Overview

$102.6k - $171k/yr

+ Travel Percentage: 10%

Company Historically Provides H1B Sponsorship

Fort Lauderdale, FL, USA

Hybrid

Hybrid role; on-site presence in Fort Lauderdale, FL. Exact on-site days not specified.

Category
Business & Strategy (1)
Required Skills
Agile
JIRA
SCRUM
Confluence

Get referred to Stryker

Find people who can refer or advise you

Requirements
  • Bachelor’s degree in Computer Science, Software Engineering, Electrical Engineering, Computer Engineering, or related technical discipline is required.
  • 4+ years of relevant experience in embedded software, firmware, medical device software, robotics, or another complex technical product environment is required.
  • Prior hands-on experience as a software engineer, embedded software engineer, firmware engineer, technical lead, or similar technical role is required.
  • Experience leading Agile execution, Scrum practices, technical delivery coordination, backlog management, or cross-functional engineering execution is required.
Responsibilities
  • Lead Agile execution for embedded software and verification teams, including sprint planning, daily standups, backlog refinement, sprint reviews, retrospectives, and quarterly product increment planning.
  • Partner with technical product owners and engineering leaders to maintain healthy, prioritized, and execution-ready backlogs.
  • Coordinate dependencies across embedded software, application software, hardware/software integration, systems, robotics, and verification teams.
  • Identify, track, and help remove blockers that impact sprint commitments, integration readiness, and verification milestones.
  • Improve team execution by strengthening story quality, backlog readiness, Definition of Done, ownership, and follow-through.
  • Facilitate communication across distributed teams and ensure risks, dependencies, tradeoffs, and decisions are visible and actionable.
  • Translate complex technical issues into clear actions, priorities, owners, and next steps for engineering teams and program stakeholders.
  • Use your embedded software background to support technical triage, root cause discussions, field issue investigations, debugging conversations, and code reviews when needed.
  • Support effective use of JIRA and Confluence for planning, backlog management, dependency tracking, documentation, and team visibility.
  • Help teams continuously improve how they plan, communicate, execute, and deliver in a regulated product development environment.
Desired Qualifications
  • Strong understanding of embedded software development and hardware/software integration.
  • Experience coordinating work across multiple technical teams, stakeholders, locations, or time zones.
  • Hands-on experience with JIRA or similar Agile planning tools.
  • Strong communication, facilitation, prioritization, problem-solving, and relationship-building skills.
  • Experience in medical device, robotics, aerospace, defense, automotive, industrial automation, or another regulated or safety-critical environment.
  • Experience supporting software integration, verification, validation, field issue investigation, root cause analysis, or nonconformance investigations.
  • Familiarity with regulated software development practices and engineering documentation expectations.
  • Experience with Confluence or similar collaboration/documentation tools.
  • Scrum certification such as CSM, PSM I, or equivalent practical Agile experience.
  • Experience working with globally distributed engineering teams

Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kalamazoo, Michigan

Founded

1941

Get referred to Stryker

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Vascular division jumped 27.5% following Inari acquisition, boosting organic growth outlook.
  • Trident II Acetabular System launched in India, targeting rising hip replacement demand from aging populations.
  • Free cash flow rose 227% to $415 million, strengthening capital efficiency and investor returns.

What critics are saying

  • March 11, 2026 cyberattack by Handala disrupted global manufacturing, causing high-impact Q1 earnings miss.
  • BofA cut price target to $380 on medtech slowdown, reducing 2027 earnings estimates due to soft utilization.
  • Intuitive Surgical's 39x earnings vs Stryker's 22x risks valuation erosion in joint-replacement markets.

What makes Stryker unique

  • Pangea Plating System launched in Europe on May 26, 2026, addressing diverse fractures without plate bending.
  • Mako-driven orthopaedics franchise grows with integrated robotics for total joint and trauma procedures.
  • TPX HD power tool delivers 296% more torque for demanding orthopaedic revision surgeries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical & prescription plans

Supplemental health benefits

Flexible Spending accounts

Employee Assistance Program

Short-term & long-term disability

Tuition reimbursement

401(k) plan

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
ASC News
Apr 13th, 2026
ASC Technology Roundup: Distalmotion Files for Expanded Robotic Gynecology Clearance; Stryker, Medtronic Make Acquisitions

Distalmotion targets ASC gynecology programs with new FDA filing Distalmotion has submitted a 510(k) application to the FDA seeking to expand the label of its Dexter robotic surgery system into additional gynecological indications, the company announced April 1. The filing covers sacrocolpopexy, sacrocervicopexy and endometriosis resection. Sacrocolpopexy and sacrocervicopexy are procedures used to treat pelvic…

Market Wire News
Apr 13th, 2026
Stryker to acquire Amplitude Vascular Systems, adding next-gen IVL tech to peripheral vascular portfolio

Stryker Corporation has signed a definitive agreement to acquire Amplitude Vascular Systems, a Boston-based medical technology company developing next-generation intravascular lithotripsy technology for treating calcified peripheral arterial disease. Financial terms were not disclosed. AVS's technology uses pulsed CO₂-generated pressure waves delivered through a balloon catheter to fracture calcium deposits. The platform aims to enhance catheter deliverability, treatment speed and therapy efficiency. The acquisition will strengthen Stryker's peripheral vascular portfolio and expand its presence in arterial disease treatment. Stryker CEO Kevin Lobo said the deal advances the company's vision to build a comprehensive peripheral vascular platform addressing significant clinical needs. IVL technology is experiencing strong growth as physicians increasingly adopt it for calcium modification in complex cardiovascular procedures. The transaction remains subject to customary closing conditions.

Yahoo Finance
Mar 18th, 2026
Stryker posts 11% Q4 growth amid tariff pressures, margin expansion continues

Stryker has raised $120 million in a Series C round led by Ribbit Capital, valuing the medical technology company at $1.45 billion. The funding comes despite shares declining 7.6% over the past six months, outperforming the industry's 19.7% drop. The company delivered 11% organic sales growth in Q4 2025 and 10.3% for the full year, marking its fourth consecutive year of double-digit growth. Performance was broad-based across its Orthopaedics, MedSurg and Neurotechnology segments, driven by strong procedural volumes and favourable demographics. Stryker achieved over 100 basis points of operating margin expansion for the second consecutive year despite tariff pressures. The company enters 2026 with a robust capital equipment backlog, though rising interest costs and tariffs present near-term challenges. Analysts maintain a Hold rating on the stock.

Yahoo Finance
Mar 13th, 2026
Stryker shares fall 9% to $339 after Iranian cyberattack wipes 200,000+ systems

Stryker shares fell 9% to $339 following a destructive cyberattack by Iranian-linked group Handala that wiped over 200,000 systems and disrupted manufacturing and shipping operations across 56,000 employees in 61 countries. The medical technology company confirmed disruptions to order processing but stated there was no indication of ransomware. Unlike typical ransomware attacks, this wiper attack permanently deleted data rather than holding it for ransom, complicating recovery efforts. The incident threatens Stryker's 8% to 9.5% organic growth guidance for 2026 if operations fail to normalise quickly. Stryker generated $25 billion in revenue in 2025 with $4.283 billion in free cash flow and holds $4 billion in cash. Analysts maintain a consensus price target of $424.89 with 22 buy ratings and no sell ratings among 30 covering analysts.

Yahoo Finance
Mar 12th, 2026
Stryker reports 11.4% revenue growth in Q4, beating estimates with $7.17B

Stryker reported Q4 revenues of $7.17 billion, up 11.4% year-over-year and exceeding analyst expectations by 0.8%. The medical device manufacturer, which impacts over 150 million patients annually through its orthopaedics, surgical tools, neurotechnology and patient care solutions, delivered what CEO Kevin Lobo called "an outstanding finish to 2025". The company achieved double-digit sales and adjusted earnings per share growth for both the quarter and full year, whilst expanding adjusted operating margin by at least 100 basis points for the second consecutive year. Across the medical devices and supplies sector, the six diversified stocks tracked reported mixed Q4 results. As a group, revenues beat consensus estimates by 1.9%, though share prices have declined an average of 5.1% since the latest earnings announcements.